Amarin Corp Plc (AMRN)

[jessellivermore]

KIWI..

Yes...The principle therapeutic effect of EPA is its ability to lower Systemic Inflammation by Increasing the number of Eicosanoid cell membrane receptors occupied by EPA vs those occupied by Arachidonic Acid and also the nuclear membrane PPAR receptors...

Acute Respiratory Distress Syndrome (ARDS) is an inflammatory condition driven by the driven by Immune response to overwhelming infection..This can be bacterial or viral..It is called septic shock in bacterial conditions where bacteria are in the circulation and are overwhelming the body's ability to combat the infection..The inflammation triggered by the infection then begins to attack the host..Whether EPA can turn the tide probably depends on when the drug is given...

Somewhere in my memory I remember there was a clinical paper where EPA was given for septic shock..I believe the paper suggested there was some benefit..It is certainly within the realm of possibility that Vascepa might offer some benefit in the COVID-19, but I don't know of any evidence on how much...Basically you need a drug that stops the virus from multiplying before it reaches the stage where it overwhelms the body..

JMO...":>) JL